- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.02. | Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials | ||
| 02.02. | GSK walks away from pioneering Wave RNA editing drug | ||
| 02.02. | Building a robust in-process testing plan for cell therapy manufacturing success | ||
| 30.01. | Amgen gives up on its once-prized eczema drug | ||
| 30.01. | AstraZeneca leans into obesity, striking wide-ranging alliance with China's CSPC | ||
| 30.01. | Politicization runs deeper than ever at FDA, risking long-term impacts | ||
| 29.01. | The biopharma industry outlook on 2026: Optimism and tension | ||
| 29.01. | Sanofi expects vaccine sales growth to dip amid 'challenging environment' | ||
| 29.01. | AstraZeneca strengthens China ties with planned $15B investment | ||
| 29.01. | Tenpoint wins FDA nod for combination presbyopia eye drop | ||
| 28.01. | Lilly bets on Seamless, delving further into genetic medicine for hearing loss | ||
| 28.01. | Drugs for cancer, arthritis and HIV on Medicare's list for 2028 price cuts | ||
| 28.01. | Halozyme buys a biotech startup; Cytokinetics launches heart drug | ||
| 28.01. | Regenxbio gene therapy trials suspended by FDA over safety worries | ||
| 27.01. | An immune drug developer raises $50M to finance its eczema drug testing | ||
| 27.01. | FDA lifts hold on an Intellia CRISPR drug trial | ||
| 27.01. | Roche, trailing in obesity, showcases new data for GLP-1 shot | ||
| 26.01. | China's edge in early-stage drugmaking 'likely to persist,' Pitchbook says | ||
| 26.01. | Sarepta, battling slowing sales, claims Duchenne gene therapy's impact grows with time | ||
| 26.01. | Biotech investor Cormorant secures $150M for another SPAC deal | ||
| 26.01. | Express Scripts considering settlement in FTC insulin price lawsuit | ||
| 26.01. | The formula for biotech success in 2026: Confidence, resilience and funding | ||
| 26.01. | The crucial role of raw material selection for success in cell therapy manufacturing | ||
| 26.01. | From detection to prevention: How sponsored testing can transform patient outcomes | ||
| 23.01. | Sanofi to seek approval of touted eczema drug despite mixed results |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.